EUVIMEDOpdag EUVIMED
MetaanalyseSystematische ÜbersichtOpen access · CC BY-NC 4.0

Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis

Shufei Yu, Shuyang Zhang, Haiyan Xu, Guangjian Yang, Fei Xu, Liang Yang, Duo Chen, Guangyu An, Yan Wang iD

BMJ Open · 2023

DOI: 10.1136/bmjopen-2021-059457 ↗

At a glance

Metaanalyse in BMJ Open, 2023. Written by Shufei Yu and 8 co-authors. Institution: Department of Radiation Oncology, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China. Major MEDLINE topics: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms. Cited 6 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objectives

Based on the acknowledged organ-specific immune microenvironment, little is known regarding the efficacy of immunotherapy in patients with lung cancer according to metastatic sites. This meta-analysis aimed to explore the efficacy of immune checkpoint inhibitors (ICIs) vs chemotherapy in patients with lung cancer with liver metastases (LM) or brain metastases (BM).

Design

Meta-analysis and systematic review. Data sources We systematically searched in electronic databases (PubMed, EMBASE, Cochrane Library and Web of Science), up to 31 January 2022. We also reviewed the abstracts from major international conferences. Eligibility criteria were randomised controlled phase II or III trials reporting the overall survival (OS) or progression-free survival (PFS) of LM or BM subsets. Data extraction and synthesis Hazard ratios (HRs) with 95% CIs for OS and PFS were extracted and aggregated using a random-effects model.

Results

Twenty-four randomised controlled trials with available outcomes for patients with BMs or LMs were identified. A total of 1124 patients with BM and 2077 patients with LM were included in the analysis. The pooled OS HR of patients with LMs was 0.83 (95% CI 0.72 to 0.95), and that of patients without LM 0.73 (95% CI 0.69 to 0.79). LM was associated with less benefits from ICIs. In patients with BM treated with ICIs, the pooled OS HR compared with the control arms was 0.71 (95% CI 0.53 to 0.94). Subgroup analyses by histology suggested that only patients with non-small cell lung cancer (NSCLC) with BM could gain benefit from ICIs (HR 0.53, 95% CI 0.41 to 0.68). BM negatively influenced efficacy of immunotherapy in patients with small cell lung cancer.

Conclusions

Our results showed immunotherapy demonstrated efficacy in patients with lung cancer with LM and BM, survival benefits dominantly favoured patients with NSCLC. Patients with lung cancer with LM obtained less benefits from ICIs than those without. Therefore, organ-specific immunotherapeutic approaches should be considered. PROSPERO registration number CRD42020212797.

Subjects

MeSH terms (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungBrain NeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapyTumor MicroenvironmentClinical Trials, Phase II as TopicRandomized Controlled Trials as Topic

Author keywords

CHEMOTHERAPYImmunologyONCOLOGY

Substances

Immune Checkpoint Inhibitors

Authors and institutions

  • Department of Radiation Oncology, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China.
  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Respiratory Medicine, Shandong Cancer Hospital and institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong, China.
  • Department of Radiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

ORCID profiles: Yan Wang

Cite

APA

Yu, S., Zhang, S., Xu, H., Yang, G., Xu, F., Yang, L., Chen, D., An, G., & Wang, Y. (2023). Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis. BMJ Open. https://doi.org/10.1136/bmjopen-2021-059457

Vancouver

Yu S, Zhang S, Xu H, Yang G, Xu F, Yang L, et al. Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis. BMJ Open. 2023. doi:10.1136/bmjopen-2021-059457

BibTeX
@article{Yu2023,
  author = {Yu, Shufei and Zhang, Shuyang and Xu, Haiyan and Yang, Guangjian and Xu, Fei and Yang, Liang and Chen, Duo and An, Guangyu and Wang, Yan},
  title = {Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis},
  journal = {BMJ Open},
  year = {2023},
  doi = {10.1136/bmjopen-2021-059457}
}
Start for free →